Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance

[Image: see text] We have previously described a cyclic tetrapeptide, 1, that displays μ opioid receptor (MOPr) agonist and δ opioid receptor (DOPr) antagonist activity, a profile associated with a reduced incidence of opioid tolerance and dependence. Like many peptides, 1 has poor bioavailability....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mosberg, Henry I., Yeomans, Larisa, Anand, Jessica P., Porter, Vanessa, Sobczyk-Kojiro, Katarzyna, Traynor, John R., Jutkiewicz, Emily M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Chemical Society 2014
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3993928/
https://ncbi.nlm.nih.gov/pubmed/24641190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm5002088
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller